EP1756085B1 - Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline - Google Patents

Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline Download PDF

Info

Publication number
EP1756085B1
EP1756085B1 EP05736074A EP05736074A EP1756085B1 EP 1756085 B1 EP1756085 B1 EP 1756085B1 EP 05736074 A EP05736074 A EP 05736074A EP 05736074 A EP05736074 A EP 05736074A EP 1756085 B1 EP1756085 B1 EP 1756085B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
methyl
chlorophenyl
xviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05736074A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1756085A1 (en
Inventor
Walter Ferdinand Maria Filliers
Rudy Laurent Maria Broeckx
Patrick René Janssen-Cilag ANGIBAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to EP05736074A priority Critical patent/EP1756085B1/en
Publication of EP1756085A1 publication Critical patent/EP1756085A1/en
Application granted granted Critical
Publication of EP1756085B1 publication Critical patent/EP1756085B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Definitions

  • the present invention relates to the diastereoselective synthesis process of 5-substituted imidazole compounds which have farnesyl tranferase inhibitory activity and to compounds used in the synthesis process for said imidazole compounds.
  • Farnesyltransferase inhibitors block the main post-translational modification of the Ras protein, thus interfering with its localization to the inner surface of the plasma membrane and subsequent activation of the downstream effectors.
  • farnesyltransferase inhibitors have subsequently been acknowledged as acting by additional and more complex mechanisms that may extend beyond Ras involving GTP-binding proteins, kinases, centromere-binding proteins and probably other farnesylated proteins.
  • R115777 (Tipifarnib) is a potent, orally active inhibitor of farnesylprotein transferase. It is one of the most advanced of the farnesylprotein transferase inhibitors currently reported to be in clinical development, being one of the agents that have progressed to phase III studies.
  • R115777 has been found to have very potent activity against neoplastic diseases. Antineoplastic activity in solid tumors, such as breast cancer, as well as in haematological malignancies, such as leukemia, have been observed. Also combination studies have been carried out demonstrating that R115777 can be safely combined with several highly active anticancer drugs.
  • racemates ( ⁇ ) (4-(3-chloro-phenyl)-6-[(6-hloro-pyridin-3-yl)-(4-methoxy-benzylamino)-(3-methyl-3 H -imidazol-4-yl)-methyl]-1-cyclopropylmethyl-1 H -quinolin-2-one (racemate 1) and ( ⁇ ) 4-(3-chloro-phenyl)-6-[(6-chloro-pyridin-3-yl)-[(4-methoxy-benzylidene)-amino]-(3-methyl-3 H -imidazol-4-yl)-methyl]-1-cydopropylmethyl-1 H -quinolin-2-one (racemate 2) are prepared.
  • intermediates of formula (XIII) can be prepared by reacting an intermediate of formula (XIV), wherein W is an appropriate leaving group, such as, for example, halo, with an intermediate ketone of formula (XV).
  • this reaction can be performed by converting the intermediate of formula (XV) into an organometallic compound, by stirring it with a strong base such as butyl lithium and subsequently adding the intermediate ketone of formula (XV). It is further indicated that although this reaction gives at first instance a hydroxy derivative (i.e.
  • R 8 is hydroxy
  • said hydroxy derivative can be converted into other intermediates wherein R8 has another definition by performing art-known (functional group) transformations.
  • the drawings of the compounds of formula (XIII), (XV) and (XTV) have been taken over from WO 97/21701 and the substituents in these drawings are as defined in WO 97/21701 .
  • WO 97/21701 it is also described (from page 7 line 32, to page 8 line 6) that the compounds of formula (XVI), wherein R is C 1-6 alkyl, R (2-8, 16-19) can be a substituent chosen from lists as defined in WO 97/21701 and R 1 has a meaning as defined in WO 97/21701 apart from hydrogen, may be prepared by hydrolysing an intermediate ether of formula (XIII), according to art-known methods, such as stirring the intermediate of formula (XIII) in an aqueous acid solution.
  • An appropriate acid can be for instance hydrochloric acid.
  • step 1 the intermediate 1-methyl imidazole in tetrahydrofuran, is mixed with a solution of n -butyllithium in a hexane solvent to which is added chlorotriethylsilane (triethylsilyl chloride), followed by a further addition of n -butyllithium in hexane, the resulting mixture being cooled to -78°C before the addition of a solution of a compound of formula (I), i.e. 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone in tetrahydrofuran.
  • a compound of formula (I) i.e. 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone in tetrahydrofuran.
  • reaction mixture is subsequently brought to room temperature, and then hydrolysed, extracted with ethyl acetate and the organic layer worked up to obtain a compound of formula (II), i.e. ( ⁇ )-6-[hydroxy(4-chlorophenyl) (1-methyl-1 H -imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone.
  • formula (II) i.e. ( ⁇ )-6-[hydroxy(4-chlorophenyl) (1-methyl-1 H -imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone.
  • step 2 the hydroxy compound of formula (II) is chlorinated with thionylchloride to form a compound of formula (III), i.e. ( ⁇ )-6-[chloro(4-chlorophenyl)(1-methyl-1 H- imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone.
  • a compound of formula (III) i.e. ( ⁇ )-6-[chloro(4-chlorophenyl)(1-methyl-1 H- imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone.
  • step 3 the chloro compound of formula (III) is treated, with NH 4 OH in tetrahydrofuran to form the amino compound of formula (IV), i.e. ( ⁇ )-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone.
  • step 4 the amino compound of formula (IV) is separated into its enantiomers by chiral column chromatography over Chiracel OD (25 cm; eluent: 100% ethanol; flow: 0.5 ml/min; wavelength: 220 nm).
  • the pure (B)-fractions are collected and recrystallised from 2-propanol resulting in R115777, the compound of formula (V).
  • the procedure described in WO97/21701 has a number of disadvantages.
  • the procedure results in the undesired formation of a corresponding compound of formula (XI), i.e. 6-[hydroxy(4-chlorophenyl) (1-methyl-1 H -imidazol-2-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone), in which the imidazole ring is attached to the remainder of the molecule at the 2-position of the ring, instead of the desired 5-position.
  • step 1 1-methyl imidazole in tetrahydrofuran is mixed with a solution of n-hexyllithium in a hexane solvent to which is added tri-iso-butylsilyl chloride, followed by a further addition of n -hexyllithium in hexane.
  • the compound of formula (I) in tetrahydrofuran is then added to the reaction mixture, keeping the temperature between -5°C and 0°C.
  • the resulting product of formula (II) is isolated by salt formation.
  • step 2 the chlorination reaction is effected by treatment of the compound of formula (II) with thionyl chloride in 1,3-dimethyl-2-imidazolidinone.
  • step 3 the chloro compound of formula (III) is treated with a solution of ammonia in methanol. After the addition of water, the compound of formula (IV), precipitates and can be isolated.
  • step 4 the compound of formula (IV) can be reacted with L-(-)-dibenzoyl tartaric acid (DBTA) to form the diastereomeric tartrate salt with formula (VI) i.e. R-(-)-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone [R-(R*,R*)]-2,3-bis(benzoyloxy)butanedioate (2:3).
  • formula (VI) i.e. R-(-)-6-[amino(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1 H )-quinolinone [R-(R*,R*)]-2,3-bis(benzoyl
  • step 5 the compound of formula (VI) is treated with aqueous ammonium hydroxide, to form the crude compound of formula (V) which is then purified by recrystallisation from ethanol to the pure compound (V).
  • the present invention solves the above described problems. It provides a new process for the preparation of a compound of formula (IV), without the need to recycle one of the enantiomers, while minimising the formation of undesired isomers and impurities and under conditions which offer economic advantages for operation on a commercial scale.
  • the present invention provides a process for the preparation of a compound of formula (XVII) wherein R is C 1-6 alkyl or C 1-6 alkylphenyl and wherein n-butyllithium is added to a solution of 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline in tetrahydrofuran, and a compound of formula (XVIII) is added to the resulting reaction mixture wherein R is C 1-6 alkyl or C 1-6 alkylphenyl, maintaining the reaction temperature at -78°C.
  • C 1-6 alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g. methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like.
  • (S(R)) in the chemical name of some compounds means that the sulfur-atom in the molecule is in the R-configuration and (S(S)) means that the sulfur-atom in the molecule is in the S-configuration.
  • the diastereomeric excess of a compound of formula (XVII) is generally higher than 80%, most preferably higher than 94 %.
  • the two diastereomers can be further purified (from the other diastereomer) by standard techniques like crystallisation or chromatography.
  • the reaction may be conveniently effected by initially preparing a solution of 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline in tetrahydrofuran, to which is added n-butyllithium in a solvent such as n -hexane at a temperature of -78 °C.
  • n-butyllithium in a solvent such as n -hexane at a temperature of -78 °C.
  • the compound of formula (XVIII) in a solvent such as tetrahydrofuran is then added to the reaction mixture, keeping the temperature at -78°C.
  • the number of equivalents of 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline used during the diastereoselective synthesis process of a compound of formula (IV) is generally one, preferably 1.25 or more.
  • the number of equivalents of n-butyllithium used during the diastereoselective synthesis process of a compound of formula (IV) is generally 1.1, preferably 1.35 or more.
  • the number of equivalents of the compound of formula (XVIII) used during the diastereoselective synthesis process of a compound of formula (IV) is generally between 1 and 1.3, preferably lower than the equivalents of 6-bromo-4-(3-chlorophenyl)-2-metboxy-quinoline and n-butyllithium.
  • the concentration of the compound of formula (XVIII) is generally higher than 0.2 mol/L, preferably higher than 0.55 mol/L, most preferably higher than 1.65 mol/L.
  • Another feature of the present invention are the compounds of formula (XVIII) and the stereochemically isomeric forms thereof wherein R is C 1-6 alkyl or C 1-6 alkylphenyl-.
  • Compounds of formula (XVIII) can be present as E and Z isomers which can rapidly interconvert.
  • Preferred compounds of formula (XVIII), are those compounds of formula (XVIII) wherein R is methylpropyl or methylphenyl, more preferably 2-methyl-2-propanyl or 4-methylphenyl.
  • Most preferred compounds of formula (IX) are compound 22, i.e. N -[(4-chlorophenyl)(1-methyl-1 H -imidazol-5-yl)methylene)]-2-methyl-2-propanesulfinamide, compound 23, i.e. N -[(4-chlorophenyl)(-1-methyl-1 H -imidazol-5-yl)methylene]- p -toluenesulfinamide, compound 25 , and compound 29.
  • the compound of formula (XVIII) wherein R is C 1-6 alkyl or C 1-6 alkylphenyl- can be made by addition of a chiral sulfinamide of formula (X), wherein R is C 1-6 alkyl or C 1-6 alkylphenyl-, in the presence of titanium (IV) ethoxide and a suitable solvent, such as dichloromethane, preferably dichloroethane or tetrahydrofuran.
  • a suitable solvent such as dichloromethane, preferably dichloroethane or tetrahydrofuran.
  • R in the chiral sulfinamide of formula (X) is preferable 2-methyl-2-propanyl or 4-methylphenyl.
  • chiral sulfinamide of formula (X) means the compound of formula (X), wherein the enantiomeric excess is 40 % or higher, preferably higher than 60 %, more preferably higher than 80 %, most preferably higher than 94 %.
  • Another feature of the present invention is a compound of formula (XVII) and the stereochemically isomeric forms thereof wherein R is C 1-6 alkyl or C 1-6 alkylphenyl-.
  • Preferred compounds of formula (XVII) are those compounds wherein R is 2-methyl-2-propyl. More preferred compound of formula (XVII) are compound 24, i.e. N -[(4-chlorophenyl)((4-(3-chlorophenyl)-2-methoxy-quinoline-6-yl)(1-methyl-1 H -imidazole-5-yl)methyl]-2-methyl-2-propanesulfinamide and compound 26.
  • a compound of formula (XVIII) can be converted into a compound of formula (XX) under acidic conditions, for example by addition of hydrochloric acid, in a suitable solvent, for example isopropanol or methanol, at a suitable temperature, for example room temperature.
  • a suitable solvent for example isopropanol or methanol
  • the quinolonone of formula (XXI) can be prepared by hydrolysing the compound of formula (XX) with an appropriate acid, such as hydrochloric acid, in a suitable solvent, such as tetrahydrofuran.
  • the quinolinone of formula (IV) can be prepared by N-alkylation of the compound of formula (XXI) with an appropriate alkylating agent, such as methyliodide, in a suitable solvent, such as tetrahydrofuran, in the presence of a suitable base, such as sodium hydroxide and a suitable phase transfer agent, such as benzyltriethylammonium chloride.
  • an appropriate alkylating agent such as methyliodide
  • a suitable solvent such as tetrahydrofuran
  • a suitable base such as sodium hydroxide
  • phase transfer agent such as benzyltriethylammonium chloride.
  • the enantiomeric excess of a compound of formula (XX), (XXI) and (IV) is generally higher than 80 %, most preferably higher than 94 %.
  • the enantiomers of formula (XX), (XXI) and (IV) can be further purified (from the other enantiomer) by standard techniques, such as crystallisation.
  • the pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formula (XVII) and (XVIII) are able to form.
  • the compounds of formula (XVII) and (XVIII) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g.
  • hydrochloric or hydrobromic acid sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic ( i . e . butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic ( i . e . butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic
  • acid addition salt also comprise the hydrates and the solvent addition forms which the compounds of formula (XVII) and (XVIII) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • stereochemically isomeric forms of compounds of formula (XVII) and (XVIII), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (XVII) and (XVIII) may possess.
  • the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
  • All stereochemically isomeric forms of the compounds of formula (XVII) and (XVIII) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
  • BTEAC benzyltriethylammonium chloride
  • DCM dichloromethane
  • DCE dichloroethane
  • EtOAc ethyl acetate
  • MeOH methanol
  • Ti(OEt) 4 means titanium (IV) ethoxide
  • THF tetrahydrofuran
  • n -Butyllithium (0.00081 mol) in hexane was added dropwise at -78°C to a mixture of 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline (0.00081 mol) in THF (3 ml) under nitrogen flow. The mixture was stirred at -78°C for 30 minutes. A solution of compound 25 (0.00065 mol) in THF (0.6 ml) was added. The mixture was stirred at - 78°C for 1 hour and 30 minutes, poured out into ice water and extracted with EtOAc. The organic layer was separated, dried (MgSO4), filtered, and the solvent was evaporated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP05736074A 2004-05-03 2005-04-28 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline Active EP1756085B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05736074A EP1756085B1 (en) 2004-05-03 2005-04-28 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04076321 2004-05-03
EP05736074A EP1756085B1 (en) 2004-05-03 2005-04-28 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
PCT/EP2005/051932 WO2005105783A1 (en) 2004-05-03 2005-04-28 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline

Publications (2)

Publication Number Publication Date
EP1756085A1 EP1756085A1 (en) 2007-02-28
EP1756085B1 true EP1756085B1 (en) 2010-06-16

Family

ID=34965002

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05736074A Active EP1756085B1 (en) 2004-05-03 2005-04-28 Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline

Country Status (11)

Country Link
US (1) US7572916B2 (xx)
EP (1) EP1756085B1 (xx)
JP (1) JP4917022B2 (xx)
CN (1) CN100567291C (xx)
AT (1) ATE471316T1 (xx)
AU (1) AU2005238222B2 (xx)
CA (1) CA2563806C (xx)
DE (1) DE602005021878D1 (xx)
ES (1) ES2346986T3 (xx)
HK (1) HK1101398A1 (xx)
WO (1) WO2005105783A1 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
ES2901506T3 (es) 2015-08-17 2022-03-22 Kura Oncology Inc Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
PT3534885T (pt) 2016-11-03 2021-04-13 Kura Oncology Inc Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
CA3100706A1 (en) * 2018-05-18 2019-11-21 Kura Oncology, Inc. Synthesis of tipifarnib

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711142B2 (en) 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
AU2001227756A1 (en) * 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001051126A1 (en) * 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2002020015A1 (en) * 2000-09-05 2002-03-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PL208238B1 (pl) * 2001-03-12 2011-04-29 Janssen Pharmaceutica Nv Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
WO2002079147A2 (en) * 2001-03-30 2002-10-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2003274759A1 (en) * 2002-10-28 2004-05-13 Chugai Seiyaku Kabushiki Kaisha Benzofuran compounds having antitumor activity
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
ES2308500T3 (es) * 2004-05-03 2008-12-01 Janssen Pharmaceutica Nv Adicion diastereoselectiva de n-metilimidazol en sulfiniminas.

Also Published As

Publication number Publication date
WO2005105783A1 (en) 2005-11-10
ES2346986T3 (es) 2010-10-22
CA2563806C (en) 2012-11-20
CN100567291C (zh) 2009-12-09
US7572916B2 (en) 2009-08-11
DE602005021878D1 (de) 2010-07-29
HK1101398A1 (en) 2007-10-18
EP1756085A1 (en) 2007-02-28
AU2005238222A1 (en) 2005-11-10
JP4917022B2 (ja) 2012-04-18
US20070293680A1 (en) 2007-12-20
ATE471316T1 (de) 2010-07-15
AU2005238222B2 (en) 2010-10-28
CA2563806A1 (en) 2005-11-10
CN1946710A (zh) 2007-04-11
JP2007536334A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
JP7085641B2 (ja) アルコラート塩基の存在下でのニコチン酸エチルとｎ－ビニルピロリドンとの反応によるラセミ体ニコチンの調製方法
JP5188501B2 (ja) モンテルカストおよびそのアミン塩類の精製方法
EP3119745B1 (en) Antifungal compound process
JP2006206597A (ja) 置換２，５−ジアミノ−３−ヒドロキシヘキサンの製造方法
EP1756085B1 (en) Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
EP1758885B1 (en) Diastereoselective addition of lithiated n-methylimidazole on sulfinimines
US7217729B2 (en) Substituted indoles, process for the production thereof and use thereof for combatting pain
WO2016174685A1 (en) Process for the enantiomeric resolution of apremilast intermediates
EP1751137B1 (en) Diastereoselective synthesis process for the preparation of imidazole compounds
SK287807B6 (sk) Spôsob prípravy 4-(3-chlórfenyl)-6-[(4-chlórfenyl)hydroxy(1- metyl-1H-imidazol-5-yl)metyl]-1-metyl-2(1H)-chinolinónu
WO2020234383A1 (en) A pharmaceutical intermediate
CN104093709B (zh) 作为醛固酮合酶抑制剂的咪唑基酮衍生物
KR20090051854A (ko) 몬테루카스트 신규한 염 및 그의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20080502

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005021878

Country of ref document: DE

Date of ref document: 20100729

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2346986

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100917

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101016

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101018

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

26N No opposition filed

Effective date: 20110317

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005021878

Country of ref document: DE

Effective date: 20110316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100916

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100616

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230310

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230310

Year of fee payment: 19

Ref country code: IT

Payment date: 20230310

Year of fee payment: 19

Ref country code: BE

Payment date: 20230315

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230314

Year of fee payment: 19

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230512

Year of fee payment: 19

Ref country code: CH

Payment date: 20230502

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240307

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240308

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240306

Year of fee payment: 20